Hemodynamic support of a 15-year-old waiting for a heart transplant: Is there a role for levosimendan in pediatric heart failure?

Arch Pediatr. 2018 Feb;25(2):132-135. doi: 10.1016/j.arcped.2017.12.003. Epub 2018 Feb 1.

Abstract

Decompensated heart failure in children requires rapid and aggressive support. In refractory cases, invasive supportive care is essential to ensure cardiac output. This results in lengthy pediatric intensive care unit (PICU) stays, secondary morbidity, and high cost. Levosimendan may help palliate the pitfalls encountered with the usual treatment. It has been shown to improve hemodynamics and decrease morbidity and mortality from heart failure in adult trials and pediatric cohorts. We report the case of a 15-year-old boy with dilated cardiomyopathy and refractory ventricular dysfunction who was weaned from continuous inotropes and discharged from the PICU with levosimendan while waiting for heart transplantation.

Keywords: Heart failure; Levosimendan; Pediatrics.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Cardiotonic Agents / therapeutic use*
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Heart Failure / surgery
  • Heart Transplantation
  • Hemodynamics
  • Humans
  • Hydrazones / therapeutic use*
  • Intensive Care Units, Pediatric
  • Male
  • Pyridazines / therapeutic use*
  • Simendan

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan